Search
for
Sort by
Research 181–210 of 1000+
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Reversible alopecia universalis secondary to PEG-interferon ??-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection
- Early stage alopecia areata is associated with inflammation in the upper dermis and damage to the hair follicle infundibulum
- Late‐onset alopecia areata: A retrospective study of 73 patients from Taiwan
- Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature
- Dermal mucin in alopecia areata – tell tale sign or incidental finding?
- Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review
- Treatments for alopecia areata: a network meta-analysis
- Profile of alopecia areata in 655 Chinese patients
- Iron deficiency and diffuse nonscarring scalp alopecia in women: More pieces to the puzzle
- Alopecia Areata
- Case Report: Paired vertex-occipital assessment reveals donor-area involvement in diffuse unpatterned alopecia
- Psychological burden of alopecia areata in patients with cancer: A narrative review
- Alopecia areata: A review
- Evidence-Based Homeopathy: A case study on alopecia areata in a 6-year-old child
- Risk factors for the development of and outcomes after diagnosis of autoimmune alopecia areata in patients with inflammatory bowel diseases
- A comparative study on therapeutic efficacy between topical dinitrochlorobenzene and topical betamethasone in alopecia areata
- Alopecia Areata
- Alopecia areata: Clinical presentation, diagnosis, and unusual cases
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Alopecia areata: An update
- Alopecia Areata
- Novel therapies for alopecia areata: The era of rational drug development
- Diffuse alopecia; nutritional factors and supplements
- Alopecia Areata
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Features of psychosocial adaptation in patients with diffuse alopecia depending on its genesis and intensity of manifestations of mental maladaptation
- Evaluation of difficult alopecia areata cases requiring histopathological confirmation
- The pathogenesis of alopecia areata
- Evidence for the off-label use of tofacitinib in alopecia areata